Publisher
Springer Science and Business Media LLC
Reference49 articles.
1. Rathod SD, Klausner JD, Krupp K, Reingold AL, Madhivanan P. Epidemiologic features of vulvovaginal candidiasis among reproductive-age women in India, infect. Dis Obstet Gynecol. 2012. https://doi.org/10.1155/2012/859071.
2. Johal HS, Garg T, Rath G, Goyal AK. Advanced topical drug delivery system for the management of vaginal candidiasis. Drug Deliv. 2016. https://doi.org/10.3109/10717544.2014.928760.
3. Saporiti AM, Gómez D, Levalle S, et al. Candidiasis vaginal: etiología y perfil de sensibilidad a agentes antifúngicos de uso clínico [Vaginal candidiasis: etiology and sensitivity profile to antifungal agents in clinical use]. Rev Argent Microbiol. 2001;33:217–22.
4. Pérez-González N, De Febrer NB, Calpena-Campmany AC, Nardi-Ricart A, Rodríguez-Lagunas MJ, Morales-Molina JA, Soriano-Ruiz JL, Fernández-Campos F, Clares-Naveros B. New formulations loading caspofungin for topical therapy of vulvovaginal candidiasis. Gels. 2021. https://doi.org/10.3390/gels7040259.
5. Rodero CF, Fioramonti Calixto GM, Cristina Dos Santos K, Sato MR, Aparecido Dos Santos Ramos M, Miró MS, Rodríguez E, Vigezzi C, Bauab TM, Sotomayor CE, Chorilli M. Curcumin-Loaded Liquid Crystalline systems for Controlled Drug Release and Improved Treatment of Vulvovaginal Candidiasis. Mol Pharm. 2018. https://doi.org/10.1021/acs.molpharmaceut.8b00507.